Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022

Rhea-AI Summary

Bausch Health Companies Inc. (NYSE:BHC) announced the presentation of a de novo abstract at The Liver Meeting® 2022 in Washington, D.C., from November 4-8. The abstract is titled "Rifaximin Plus Lactulose Versus Lactulose Alone for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Pooled Subgroup Analysis." XIFAXAN® (rifaximin) is indicated for the reduction of overt hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. The company emphasizes safety information related to XIFAXAN use.

Positive

• Presentation of significant clinical data at a reputable medical conference.
• XIFAXAN is indicated for important gastrointestinal conditions, possibly expanding market opportunities.

Negative

• Potential hypersensitivity reactions could impact patient safety and market perception.
• Concerns regarding Clostridium difficile-associated diarrhea may deter some prescribing.

LAVAL, QC / ACCESSWIRE / November 4, 2022 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ("Salix"), today announced one de novo abstract that is being presented at The Liver Meeting® 2022, organized by the American Association for the Study of Liver Diseases (AASLD), which is taking place November 4-8 in Washington, D.C.

The abstract being presented at AASLD's The Liver Meeting 2022 is:

• Sanyal, A. et al. "Rifaximin Plus Lactulose Versus Lactulose Alone for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Pooled Subgroup Analysis."

About XIFAXAN®
Indications
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

• XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
• Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
• There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
• Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
• In clinical studies, the most common adverse reactions for XIFAXAN were:
  • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
  • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
• INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
• XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

About Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements about the future performance of the Company, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Company's overall business, including those more fully described in the Company's most recent annual report on Form 10-K and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian securities administrators, which factors are incorporated herein by reference.

©2022 Salix Pharmaceuticals or its affiliates.
The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A. to Salix Pharmaceuticals or its affiliates.
SAL.0119.USA.22

Investor Contact:
Christina Cheng
ir@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)

Media Contact:
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785

Gianna Scalera
salixcommunications@bauschhealth.com
(908) 541-2110

SOURCE: Salix Pharmaceuticals

View source version on accesswire.com:
https://www.accesswire.com/723896/Salix-Will-Present-Rifaximin-Data-at-AASLDs-The-Liver-MeetingR-2022

FAQ

What is the significance of the abstract presented by Bausch Health at The Liver Meeting 2022?

The abstract presents data on the effectiveness of Rifaximin in reducing the recurrence of hepatic encephalopathy.

What are the indications for XIFAXAN as reported in the press release?

XIFAXAN is indicated for the reduction of overt hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea.

What are the safety concerns related to XIFAXAN mentioned in the press release?

Safety concerns include hypersensitivity reactions and the risk of Clostridium difficile-associated diarrhea.

When and where was The Liver Meeting 2022 held?

The Liver Meeting 2022 was held in Washington, D.C. from November 4-8, 2022.

What company presented at The Liver Meeting 2022?

Bausch Health Companies Inc. presented at The Liver Meeting 2022.